Humacyte (HUMA) vs Outlook Therapeutics (OTLK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Outlook Therapeutics (OTLK) has outperformed Humacyte (HUMA) over the past year, losing 49.6% versus a loss of 71.3%. Over five years, HUMA leads with a -95.4% price change compared with -98.6% for OTLK. Outlook Therapeutics is the larger company by market cap ($143.6 million vs $131.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUMA | OTLK |
|---|---|---|
| Share price | $0.4723 | $0.59 |
| Market cap | $131.20M | $143.63M |
| 1-day change | -1.19% | +3.15% |
| YTD return | -50.85% | -62.66% |
| 1-year return | -71.29% | -49.57% |
| 5-year return | -95.38% | -98.60% |
| EPS (TTM) | $-0.51 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.90 | $2.54 |
| 52-week low | $0.46 | $0.161 |
| Distance from 52-week high | -75.08% | -76.75% |
| Analyst consensus | buy | none |
| Avg. price target upside | +245.12% | +752.54% |
| Average volume | 6.35M | 13.58M |
| Shares outstanding | 277.80M | 243.45M |
| Employees | 184 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OTLK has outperformed HUMA by 21.7 percentage points over the past year.
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Healthcare · Biotechnology · 184 employees
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Healthcare · Biotechnology · 17 employees
HUMA vs OTLK FAQ
Which is bigger, Humacyte or Outlook Therapeutics?
Outlook Therapeutics (OTLK) is larger, with a market capitalization of $143.63M compared with $131.20M for Humacyte (HUMA).
Which stock has performed better over the past year, HUMA or OTLK?
OTLK returned -49.57% over the past 12 months, compared with -71.29% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Humacyte and Outlook Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.